search
Back to results

Intraperitoneal Lidocaine in Ovarian Cancer Surgery

Primary Purpose

Ovarian Cancer, Post Operative Pain

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
intraperitoneal lidocaine analgesic or normal saline as control
Sponsored by
Peking University Third Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ovarian Cancer focused on measuring Postoperative intraperitoneal lidocaine, Intraperitoneal analgesic, Ovarian cancer, Prognosis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • The American Society of Anesthesiologists (ASA) rated them as grade I to II, aged 18 to 75 years.
  • Patients undergoing elective laparotomy for ovarian cancer reduction (surgical resection includes the whole uterus with or without double adnexa, lymph node biopsy, dissection, appendectomy, etc.).

Exclusion Criteria:

  • Suffering from mental illness or unable to cooperate with pain and related index scoring, unable to use automatic pump.
  • Peritoneal infection existed before surgery
  • Past history of arrhythmia
  • Severe liver and kidney dysfunction existed before surgery
  • Known allergy to local anesthetics
  • Do not agree to participate in the research

Sites / Locations

  • Peking University Third Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

intraperitoneal analgesic group

control group

Arm Description

Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump. At the same time, patients in both groups were connected with intravenous controlled intravenous controlled analgesia (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.

Before the end of surgery, patients in the control group (C group) were extensively sprayed with 20mL normal saline intraperitoneally before the peritoneum was sutured. The surgeon placed an intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. In the control group, 0.9% normal saline was injected intraperitoneally with 10mL/h, and the total volume in the pump was 720mL. At the same time, patients in both groups were connected with intravenous controlled analgesia pump (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.

Outcomes

Primary Outcome Measures

Postoperative analgesic use
Postoperative intravenous analgesia pump pressing time (recording the time by the electronic analgesia pump) and times (including effective and ineffective pressing times, recording by numbers), intravenous analgesia pump drug usage[sufentanil (µg)].

Secondary Outcome Measures

Survival time (months)
Postoperative survival time (months).
Disease free survival time (months)
Time between surgery to cancer relapse (months).
Recurrence (yes/no, if yes ,record recurrence date)
Whether the cancer relapse.
Postoperitive chronic pain duration (months)
Postoperitive chronic pain duration (months), if present, record the location of the pain.

Full Information

First Posted
May 31, 2022
Last Updated
July 11, 2022
Sponsor
Peking University Third Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT05450055
Brief Title
Intraperitoneal Lidocaine in Ovarian Cancer Surgery
Official Title
A Randomized Controlled Trial to Investigate Effect of Postoperative Intraperitoneal Lidocaine on the Analgesic and Prognosis of Patients With Ovarian Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 18, 2022 (Anticipated)
Primary Completion Date
July 30, 2024 (Anticipated)
Study Completion Date
July 30, 2029 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Peking University Third Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The main objective of this trial is to improve the postoperative analgesia effect and prognosis of patients with ovarian cancer after laparotomy surgery. This is a randomized, double-blind, controlled trial to evaluate analgesia and patient outcomes after local peritoneal anesthesia after surgery.
Detailed Description
This is a prospective, randomized, controlled clinical study. Sixty patients were expected to participate in a centralized randomized study method divided into two groups of 30 patients per group: the intraperitoneal analgesic group and the normal saline control group. Standard routine anesthesia was performed in both groups using the same method, and intravenous analgesia pump was routinely used in clinical use after surgery. The intraperitoneal analgesic group was continuously pumped with local anesthetics into the abdominal cavity, while the control group was pumped with normal saline. Visual analogue pain score (VAS), amount of remedial analgesia and use of analgesia pump were recorded at 1, 2, 4, 8, 12, 24, 36, 48, 60 and 72 hours after operation. Record the time when the patient began drinking and eating, and the time when gastrointestinal function (defecation or exhaust) recovered. The time of starting to walk on the ground (including the time of needing attendant assistance or not) and the time of meeting the standard of postoperative discharge preparation. Perioperative peripheral blood samples were collected for five times (T0 before anesthesia induction, T1 after tracheal extubation, T2 on the morning of the first postoperative day, T3 on the morning of the second postoperative day, and T4 on the morning of the third postoperative day), and inflammatory factors and tumor-related indicators were monitored. Adverse reactions were recorded. The prognosis of the patients was followed up 5 years after operation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ovarian Cancer, Post Operative Pain
Keywords
Postoperative intraperitoneal lidocaine, Intraperitoneal analgesic, Ovarian cancer, Prognosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Sixty patients were expected to participate in a centralized randomized study method divided into two groups of 30 patients per group: the intraperitoneal analgesic group and the normal saline control group.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
intraperitoneal analgesic group
Arm Type
Experimental
Arm Description
Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump. At the same time, patients in both groups were connected with intravenous controlled intravenous controlled analgesia (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
Arm Title
control group
Arm Type
Placebo Comparator
Arm Description
Before the end of surgery, patients in the control group (C group) were extensively sprayed with 20mL normal saline intraperitoneally before the peritoneum was sutured. The surgeon placed an intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. Patients in both groups were routinely given flurbiprofen axel 50mg intravenously for analgesia. Local infiltration anesthesia was performed with 20mL 1% lidocaine at the incision area. In the control group, 0.9% normal saline was injected intraperitoneally with 10mL/h, and the total volume in the pump was 720mL. At the same time, patients in both groups were connected with intravenous controlled analgesia pump (PCIA) : sufentanil 100µg to 100mL normal saline, background dose of 2mL/h, single push injection of 0.5mL, locked for 15 minutes.
Intervention Type
Procedure
Intervention Name(s)
intraperitoneal lidocaine analgesic or normal saline as control
Intervention Description
Before the end of surgery, patients in the experimental group (L group) were extensively sprayed with 20mL (100mg) 0.5% lidocaine intraperitoneally before the peritoneum was sutured. The surgeon placed intraperitoneal catheter with the catheter tip above the vaginal end while placing percutaneous drainage tube. The intraperitoneal catheter was connected to the electronic analgesia pump, and the infusion of 0.5% lidocaine 10mL/h was interrupted from 1 to 72h after surgery, with a total volume of 720mL in the pump.
Primary Outcome Measure Information:
Title
Postoperative analgesic use
Description
Postoperative intravenous analgesia pump pressing time (recording the time by the electronic analgesia pump) and times (including effective and ineffective pressing times, recording by numbers), intravenous analgesia pump drug usage[sufentanil (µg)].
Time Frame
Postoperative 72 hours
Secondary Outcome Measure Information:
Title
Survival time (months)
Description
Postoperative survival time (months).
Time Frame
Postoperative 5 years
Title
Disease free survival time (months)
Description
Time between surgery to cancer relapse (months).
Time Frame
Postoperative 5 years
Title
Recurrence (yes/no, if yes ,record recurrence date)
Description
Whether the cancer relapse.
Time Frame
Postoperative 5 years
Title
Postoperitive chronic pain duration (months)
Description
Postoperitive chronic pain duration (months), if present, record the location of the pain.
Time Frame
Postoperative 5 years
Other Pre-specified Outcome Measures:
Title
Start drinking and eating time (hours)
Description
Time when the patients start drinking and eating.
Time Frame
During the time in the hospital. Up to 30 days post operation.
Title
Time for recovery of gastrointestinal function (defecation or exhaust)(hours)
Description
Time to the patients bowel movement recover.
Time Frame
During the time in the hospital. Up to 30 days post operation.
Title
The time for starting to walk.
Description
Record the time of walk with attendant assistance (hours), and by theirselves____ (hours).
Time Frame
During the time in the hospital. Up to 30 days post operation.
Title
The standard time of postoperative discharge preparation ____ (hours)
Description
Postoperative discharge preparation standards include: Walk independently, gastrointestinal function (to eat, drink, defecate) returned to normal, with oral analgesics, appropriate control without a mild pain, symptoms of nausea and vomiting, a local infection (redness, tenderness) or systemic infection, fever, c-reactive protein or increase white blood cell count), no other complications (bleeding, respiratory dysfunction, Deep vein thrombosis, etc.
Time Frame
During the time in the hospital. Up to 30 days post operation.
Title
Drainage tube and fluid.
Description
Drainage tube removal time ____(hours), drainage volume ____(ml), drainage flow character ____(color/transparent/other).
Time Frame
During the time in the hospital. Up to 30 days post operation.
Title
Local anesthetic toxicity
Description
Frequency of occurrence: Times of occurrence (number) The time of occurrence from surgery (hours) Symptoms (record) Treatment (record)
Time Frame
During the time in the hospital. Up to 30 days post operation.
Title
Nausea and vomiting:
Description
Nausea and vomiting: Times of vomiting(number) The time of occurrence from surgery (hours) Treatment (record) Postoperative nausea score was recorded by numbers 0-3:0 = no nausea, 1= mild nausea and vomiting, which did not require drug treatment, 2= moderate nausea, which could be controlled by ondansetron, 3= severe nausea, which did not respond to ondansetron.
Time Frame
During the time in the hospital. Up to 30 days post operation.

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The American Society of Anesthesiologists (ASA) rated them as grade I to II, aged 18 to 75 years. Patients undergoing elective laparotomy for ovarian cancer reduction (surgical resection includes the whole uterus with or without double adnexa, lymph node biopsy, dissection, appendectomy, etc.). Exclusion Criteria: Suffering from mental illness or unable to cooperate with pain and related index scoring, unable to use automatic pump. Peritoneal infection existed before surgery Past history of arrhythmia Severe liver and kidney dysfunction existed before surgery Known allergy to local anesthetics Do not agree to participate in the research
Facility Information:
Facility Name
Peking University Third Hospital
City
Beijing
ZIP/Postal Code
100191
Country
China

12. IPD Sharing Statement

Learn more about this trial

Intraperitoneal Lidocaine in Ovarian Cancer Surgery

We'll reach out to this number within 24 hrs